Literature DB >> 34001220

Inverse relationship between serum adenosine deaminase levels and islet beta cell function in patients with type 2 diabetes.

Jie Cao1, Hong Wang1, Jian-Bin Su2, Xue-Qin Wang3, Dong-Mei Zhang4, Xiao-Hua Wang1, Wang-Shu Liu1, Xiao-Qin Ge1.   

Abstract

OBJECTIVE: Type 2 diabetes (T2D) is a chronic low-grade inflammatory disease, which characterized by islet beta cell dysfunction. Serum adenosine deaminase (ADA) is an important enzyme that regulates the biological activity of insulin, and its levels are greatly increased in inflammatory diseases with insulin resistance. The present study was designed to explore the relationship between serum ADA levels and islet beta cell function in patients with T2D.
METHODS: This cross-sectional study recruited 1573 patients with T2D from the Endocrinology Department of the Affiliated Hospital 2 of Nantong University between 2015 and 2018. All participants were received serum ADA test and oral glucose tolerance test (OGTT). Insulin sensitivity index (assessed by Matsuda index using C-peptide, ISIM-cp), insulin secretion index (assessed by ratio of area under the C-peptide curve to glucose curve, AUCcp/glu) and islet beta cell function (assessed by insulin secretion-sensitivity index 2 using C-peptide, ISSI2cp) were derived from OGTT. And other clinical parameters, such as HbA1c, were also collected.
RESULTS: It was showed that HbA1c was significantly increased, while ISIM-cp, AUCcp/glu and ISSI2cp significantly decreased, across ascending quartiles of serum ADA levels. Moreover, serum ADA levels were negatively correlated with ISSI2cp (r = - 0.267, p < 0.001). Furthermore, after adjusting for other clinical parameters by multiple linear regression analysis, serum ADA levels were still independently associated with ISSI2cp (β =  - 0.125, t =  - 5.397, p < 0.001, adjusted R2 = 0.459).
CONCLUSIONS: Serum ADA levels are independently associated with islet beta cell function in patients with T2D.

Entities:  

Keywords:  Adenosine deaminase; Islet beta cell function; Type 2 diabetes

Year:  2021        PMID: 34001220     DOI: 10.1186/s13098-021-00671-2

Source DB:  PubMed          Journal:  Diabetol Metab Syndr        ISSN: 1758-5996            Impact factor:   3.320


  3 in total

1.  Glucose clamp technique: a method for quantifying insulin secretion and resistance.

Authors:  R A DeFronzo; J D Tobin; R Andres
Journal:  Am J Physiol       Date:  1979-09

2.  Adenosine Deaminase as a Useful Biomarker for Diagnosis and Monitoring of Inflammatory Bowel Disease.

Authors:  Mariyana Yordanova; Daniela Gerova; Antoniya Atanassova; Bistra Galunska
Journal:  Clin Lab       Date:  2020-07-01       Impact factor: 1.138

3.  Adenosine deaminase activity in the serum of type 2 diabetic patients.

Authors:  Naciye Kurtul; Sadrettin Pence; Ersin Akarsu; Hasan Kocoglu; Yemliha Aksoy; Hülya Aksoy
Journal:  Acta Medica (Hradec Kralove)       Date:  2004
  3 in total
  1 in total

1.  Increased levels of serum adenosine deaminase and increased risk of diabetic peripheral neuropathy in type 2 diabetes.

Authors:  Chao Yu; Lei Zhuang; Feng Xu; Li-Hua Zhao; Xiao-Hua Wang; Chun-Hua Wang; Li-Yan Ning; Xiu-Lin Zhang; Dong-Mei Zhang; Xue-Qin Wang; Jian-Bin Su
Journal:  Front Endocrinol (Lausanne)       Date:  2022-10-04       Impact factor: 6.055

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.